RxDoctor Payments DataLook up a doctor →

Dustin Davis, DO

Family Medicine · Georgetown, DENPI 1417044157

Payments from drug & device makers

$16,600in general payments, 2019–2025

Across 860 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • Pfizer$861
  • plus $6K from 29 others

What the payments were for

  • Food & beverage$16,46599%
  • Education$1351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,600 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$98,767
Medicare patients
139
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$101,119
EliquisApixaban67$85,434
OzempicSemaglutide50$81,011
FarxigaDapagliflozin Propanediol36$55,255
XareltoRivaroxaban22$28,295
JardianceEmpagliflozin14$24,453
Repatha SureclickEvolocumab22$23,725
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,989
MyrbetriqMirabegron20$18,845
LinzessLinaclotide11$16,025
Aimovig AutoinjectorErenumab-Aooe12$11,229
NexlizetBempedoic Acid/Ezetimibe11$8,170
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,474
Rosuvastatin Calcium148$6,438
Ezetimibe70$6,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,171$101,11959 claims
PfizerEliquis$861$85,43467 claims
Novo NordiskOzempic$2,306$81,01150 claims
AstraZenecaFarxiga$2,012$55,25536 claims
Johnson & JohnsonXarelto$304$28,29522 claims
Boehringer IngelheimJardiance$606$24,45314 claims
Astellas Pharma US IncMyrbetriq$433$18,84520 claims
AbbVieLinzess, Synthroid$1,964$17,03424 claims
Esperion Therapeutics, Inc.Nexlizet$206$8,17011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.

Other family medicine in Georgetown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →